Physiologically-based pharmacokinetic (PBPK) model of bosentan
A whole-body PBPK model of bosentan is distributed within this repository. The structure of this model includes the OATP1B1/1B3-mediated active uptake, CYP2C9- and CYP3A4-mediated metabolism of bosentan, and bosentan-mediated induction of CYP3A4 and inhibition of OATP1B1/1B3. The model was developed and evaluated for describing bosentan's hepatic disposition and bosentan in systemic plasma and excreta. Details can be found in reference [1]
The PBPK model was developed using OSP Suite Version 11.0 (Build - 150).
The model is distributed under the GPLv2 License.
[1] Huang MC, Macente J, Heylen S, Ning C, De Vos K, Deferm N, Annaert P. Predicting Systemic and Liver Bosentan Exposure Using Physiologically-Based Pharmacokinetic Modeling. (2025) CPT Pharmacometrics Syst Pharmacol. doi: 10.1002/psp4.70085.